Global Multiplex Assays Market Driven by High-Throughput Diagnostic Demand
Posted on 02 Jun 2026
Multiplex assays enable simultaneous detection and measurement of multiple analytes in a single sample, supporting faster analysis across diagnostics, biomarker discovery, drug development, and life sciences research. Their use is expanding in infectious disease testing, oncology, autoimmune disease assessment, companion diagnostics, and disease profiling, where laboratories need high-throughput tools that deliver broader molecular and protein insights from limited sample volumes. The global multiplex assays market is projected to grow from USD 7.15 billion in 2026 to USD 10.65 billion by 2031, at a compound annual growth rate of 8.3%.
These are the latest findings of MarketsandMarkets (Delray Beach, FL, USA), a market research and consulting firm.
Growth in the multiplex assays market is expected to be driven by rising demand for high-throughput diagnostic tools and the ability to analyze multiple biomarkers in a single sample. The increasing incidence of infectious diseases, cancer, and autoimmune disorders is also contributing to demand, along with broader adoption of precision medicine and companion diagnostics. Improvements in PCR technology, immunoassays, sequencing techniques, and sample-to-answer platforms are further expanding the use of multiplex testing across clinical and research settings.
Market growth is also being supported by technological progress in diagnostics and life sciences research. Highly sensitive multiplex platforms, advances in assay chemistry, and growing laboratory automation have improved testing efficiency and workflow productivity. In addition, advanced software, cloud connectivity, and data analytics are helping laboratories manage complex assay outputs and support more informed decision-making. Multiplex tests are becoming increasingly important for disease profiling, biomarker measurement, and precise analysis across patient groups.
Among products and services, consumables accounted for the largest share of the multiplex assays market in 2025, representing 67.9% of the market. This is primarily because consumables are used in every testing cycle, unlike instruments that are generally tied to one-time capital purchases. By type, protein multiplex assays are expected to register the highest CAGR during the forecast period, supported by their expanding use in biomarker analysis, immunology, oncology, and drug development.
In terms of technology, flow cytometry accounted for the largest market share in 2025. The market also includes fluorescence detection, multiplex real-time PCR, luminescence, next-generation sequencing, and other techniques. The strong position of flow cytometry is attributed to its sensitivity, multiparametric analysis capability, and utility in immunology, oncology, and cellular research. The rising adoption of molecular diagnostics, increasing number of diagnostic centers, and continued advancements in automation and analysis are also expected to drive demand for multiplex assays.
Clinical diagnostics represented the largest application segment in 2025. Growth in this area is being driven by rising demand for rapid, accurate multi-target disease identification, increasing incidence of infectious diseases and cancers, and growing use of syndromic testing panels in healthcare facilities. The research and development segment also remains significant, supported by biomarker discovery and global drug development activities.
Pharmaceutical and biotechnology companies accounted for the largest share among end users in 2025. The market also includes hospitals and diagnostic laboratories, academic and research institutes, contract research organizations, and other end users. Rising test volumes, the need for multiplexed analysis, and growing adoption of automation in diagnostic procedures are among the key factors supporting demand from pharmaceutical and biotechnology companies.
Geographically, North America dominated the multiplex assays market in 2025. The market is also segmented into Asia Pacific, Latin America, Europe, and the Middle East and Africa. North America’s leading position is attributed to its advanced healthcare industry, presence of established biotechnology and diagnostics companies, and adoption of innovative technologies. The region also benefits from a large number of advanced hospitals, research institutes, and diagnostic centers, along with rising demand linked to infectious diseases and cancer.
Related Links
MarketsandMarkets
